A clinical trial in older volunteers showed vaccine safety.
The British-Swedish pharmaceutical company AstraZeneca, together with British biologists, announced the completion of the second phase of the trial of the coronavirus vaccine AZD1222. As a result, the effectiveness of the vaccine for the elderly over 56 years old was proven.
Preliminary results from the second phase of the AZD1222 vaccine trial, being developed at Oxford University, showed that the elderly developed immunity for up to a year. At the same time, no dangerous side effects from vaccine administration were observed.
The third phase of clinical trials of the vaccine is already underway in Japan, Brazil, India, South Africa and the UK. Tests on volunteers in the United States are also expected to resume.
Photo: from open sources